CORT Financial Facts

Net loss and comprehensive loss: 2.59M
Research and development: 7.05M
See Full Income Statement

Total liabilities and stockholders' equity: 62.93M
Total current assets: 59.78M
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date 1/27/17 *Est. EPS Growth Rate +500.0% *Last Qtr.
Average EPS % Beat Rate +187.5% Revenue Growth Rate +63.2% *Last Qtr.
Average % Move 1-Wk after EPS +10.0% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/1/16 Q316 $0.04$0.01 +$0.03$21.7M$21.24M = Details
8/2/16 Q216 $0.03$0.01 +$0.02$19.7M$18.36M = Details
5/3/16 Q116 $0.02$0.01 +$0.01$16.1M$16.32M = Details
1/28/16 Q415 $0.01-$0.02 +$0.03$15M$15.5M = Details
11/5/15 Q315 -$0.01-$0.02 +$0.01$13.3M$13.9M N/A Details
8/5/15 Q215 -$0.02-$0.04 +$0.02$12M$11.67M N/A Details
5/7/15 Q115 -$0.05-$0.04 -$0.01$10.1M$10.5M N/A Details
3/4/15 Q414 -$0.02-$0.06 +$0.04$9.01M$9.1M N/A Details